East-West academic-industry research collaboration to identify lung cancer biomarkers

October 28, 2020
iProgen Biotech Inc.

Two Japanese institutions, a Korean biotechnology start-up, and a Canadian biotech company have entered into a research collaboration to identify biomarkers unique to lung cancer cells suitable for targeted therapeutics. As of October 13, 2020, Japan’s largest comprehensive research organization, RIKEN; Keio University of Japan; iProgen Biotech Inc. of Canada, and iPrime Therapeutics Co., Ltd … Continue reading East-West academic-industry research collaboration to identify lung cancer biomarkers

Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19

October 27, 2020
Aurinia Pharmaceuticals Inc.

VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced the funding and initiation of an open-label exploratory trial evaluating the antiviral effects of voclosporin in kidney transplant recipients (KTRs) with COVID-19 (SARS-CoV-2) – the VOCOVID study. The single-center, … Continue reading Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19

Canada’s Prime Minister, Justin Trudeau, Announced Today Precision NanoSystems Will Receive $18.2 Million from the Government of Canada to Develop an RNA Vaccine for COVID-19

October 23, 2020
Precision NanoSystems Inc.

PNI will use the investment to advance a cost-effective Made-in-Canada COVID-19 vaccine PNI offers expertise in self-amplifying mRNA vectors, lipid-based drug delivery systems and nanomedicine manufacturing PNI will contribute to Canada’s ability to secure an effective COVID-19 vaccine and build technologies towards enabling rapid response against future pandemics Vancouver BC. Precision Nanosystems, Inc. (PNI), a … Continue reading Canada’s Prime Minister, Justin Trudeau, Announced Today Precision NanoSystems Will Receive $18.2 Million from the Government of Canada to Develop an RNA Vaccine for COVID-19

Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020

October 22, 2020
Aurinia Pharmaceuticals Inc.

– Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care – – Voclosporin pharmacokinetic data supports consistent dose-response, potentially eliminating the need for therapeutic drug monitoring – VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused … Continue reading Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020

iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 – November 3rd, 2020

October 21, 2020
iCo Therapeutics Inc.

Vancouver, British Columbia–(Newsfile Corp. – October 21, 2020) – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or “the Company”) and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that two poster presentations regarding iCo’s Oral Amphotericin B technology (iCo-019) will be highlighted at the AAPS 2020 PharmSci 360 Virtual Meeting October 26 – … Continue reading iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 – November 3rd, 2020

Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083’s Participation in the GBM AGILE Registrational Study

October 21, 2020
Kintara Therapeutics, Inc. 

– Adaptive Clinical Trial Platform in Glioblastoma Multiforme – – Expected to serve as basis for VAL-083’s new drug application (NDA) submission and registration – Expansion of clinical site involvement with 31 U.S. sites actively enrolling patients; international sites expected to come online in next 12 months – Anticipated enrollment of 150-200 subjects into the … Continue reading Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083’s Participation in the GBM AGILE Registrational Study

Praxis SCI Accelerate Program – Applications Now Open

October 20, 2020
Praxis Spinal Cord Institute

October 20, 2020 – Vancouver, BC – Praxis #SCIAccelerate – applications are now open! Our program looks for post-prototype #spinalcordinjury innovations impacting quality of life, and #healthtech #medtech with greater reach beyond #SCI. Apply here.   Apply to Praxis #SCIAccelerate today. Rapidly scale your #healthtech #medtech through expert mentoring, SCI consumer & research validation, $50k … Continue reading Praxis SCI Accelerate Program – Applications Now Open

Symvivo Corporation receives funding for COVID-19 Vaccine Program

October 20, 2020
Symvivo Corporation

Contribution of up to $2.8 million will support clinical advancement of bacTRL-Spike™ oral vaccine candidate Proprietary bacTRL™ platform can be used to produce vaccines that can be stored at room temperature and administered orally rather than injected BURNABY, British Columbia, October 20, 2020 – Symvivo Corporation today announced that it is receiving advisory services and … Continue reading Symvivo Corporation receives funding for COVID-19 Vaccine Program

Sonic Incytes Announces FDA Clearance and US Launch of VelacurTM to Help Manage Emerging Health Crisis

October 20, 2020
Sonic Incytes Medical Corp.

Northwell Health is one of first medical centers to trial VelacurTM Vancouver, Canada, October 20, 2020 – Sonic Incytes Medical Corporation is pleased to announce the US commercial release of VelacurTM, the world’s first handheld 3D liver health assessment tool with diagnostic accuracy comparable to Magnetic Resonance Imaging (MRI). The introduction and availability of this … Continue reading Sonic Incytes Announces FDA Clearance and US Launch of VelacurTM to Help Manage Emerging Health Crisis

Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel

October 20, 2020
Neoleukin Therapeutics, Inc.

SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Holly K. Vance as General Counsel. Ms. Vance joins Neoleukin from the Bill & Melinda Gates Foundation, where she served as Associate General Counsel and provided legal and strategic guidance on investments and transactions … Continue reading Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel